Last Update: Aug 02, 2024
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
ClinicalTrials.gov Identifier:
Novartis Reference Number:CMBG453B12206B
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study is intended to collect safety data from participants who completed the parent
protocols but are still benefiting from study treatment. The study population consists of
participants who tolerate study treatment of the parent studies. Collecting safety
information from long-term exposure might offer the unique opportunity to detect rare
Adverse Events. This is a multicenter, open label, roll-over study to collect and assess safety of
sabatolimab in participants who are treated in current Novartis-sponsored parent studies
and who are benefiting from continued study treatment including sabatolimab as judged by
the investigator.

There is no conventional screening period in this study as participants are expected to
transition directly from treatment on the parent protocol to treatment on this roll-over
protocol. Participants who are candidates for the roll-over protocol will be evaluated by
the investigator in the parent protocol for eligibility for the roll-over protocol. If
eligible, the parent protocol end of treatment visit will be performed and the informed
consent for the roll-over protocol will be signed. Participants then continue treatment
on this protocol with the next planned dose of sabatolimab as monotherapy or with other
combination agent(s).

The treatment with sabatolimab and combination agent(s), as applicable, is continued
according to the schedule in the parent study. Adverse events (AEs) will be collected
continuously throughout the study and participants will be questioned about adverse
events at each visit.

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Phase2
Recruiting
70
Feb 13, 2023
Feb 14, 2028
All
12 Years - 99 Years (Child, Adult, Older Adult)

Interventions

Drug

azacitidine

Solution for subcutaneous injection or intravenous infusion
Drug

decitabine

Solution for intravenous infusion
Drug

INQOVI (oral decitabine)

Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
Drug

sabatolimab

Solution for intravenous infusion
Drug

spartalizumab

Solution for intravenous infusion
Drug

venetoclax

Tablet for oral administration

Eligibility Criteria

Inclusion Criteria:

1. Participant is currently enrolled in a Novartis-sponsored study with sabatolimab, is
being treated with sabatolimab, and has fulfilled all requirements in the parent
study.

2. Participant is currently benefiting from the treatment with sabatolimab as
determined by guidelines of the parent protocol and investigator's judgment.

3. Participant has demonstrated compliance, as assessed by the investigator, with the
parent study protocol requirements.

4. Willingness and ability to comply with scheduled visits, treatment plan and any
other study procedures.

5. Written informed consent obtained prior to enrolling in the roll-over study.

Exclusion Criteria:

1. Participants in cohorts or treatment groups not receiving sabatolimab in the parent
protocol.

2. Participant has been permanently discontinued from sabatolimab treatment in the
parent study due to unacceptable toxicity, non-compliance to study procedures,
withdrawal of consent or any other reason.

3. Participant currently has unresolved toxicities for which sabatolimab dosing has
been interrupted in the parent study (participants meeting all other eligibility
criteria may be enrolled once toxicities have resolved to allow sabatolimab dosing
to resume).

4. Pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a
female after conception confirmed by a positive serum hCG laboratory test and until
the termination of gestation.

5. Participant not willing to comply with the contraception requirements outlined in
the exclusion criteria of the parent protocol.

6. Local access to commercially available sabatolimab for parent protocol indications.

Other protocol-defined Inclusion/Exclusion may apply.

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals